Elevated S100A9 expression in tumor stroma functions as an early recurrence marker in early-stage OSCC patients through increased tumor cell invasion, angiogenesis, macrophage recruitment and IL-6 production [56]. This evidence concerns the gene S100A9 and neoplasm.